Treatment with doxycycline (DOXI) reduces ventricular remodeling and decreases the susceptibility of arrhythmias after myocardial infarction (MI), probably due to its inhibitory effect on metalloproteinases, inflammatory mediators, and oxidative stress. We evaluated the effect of DOXI on heart rate variability (HRV) in rats with MI. Infarcted rats (coronary ligation) or control animals (sham-operated), were treated with DOXI (30 mg/kg/day) or vehicle for 4 weeks (N=7-10/group). Rats were implanted with subcutaneous electrodes and, on the following day, had ECG recorded for 30 min. Series of RR intervals were generated to calculate HRV indices. DOXI-treated control rats had lower heart rate (HR) than vehicle-treated counterparts (327±7 vs. 352±7 bpm). Infarcted rats, treated or not, had similar heart rate (344±7 and 350±6 bpm). The standard deviation of RR intervals was similar among groups, but the differences between successive RR (RMSSD) were smaller in DOXI-treated sham-operated rats (4.0±0.5 vs. 6.3±0.9 ms). No differences were observed in RMSSD in rats with MI. Spectral analysis showed that the LF/HF ratio was lower in DOXI-treated control rats (0.32±0.05 vs. 0.62 ± 0.07). There was no difference in the LF/HF ratio in infarcted rats treated with DOXI or vehicle. The symbolic analysis, as described by Porta et al., showed a lower occurrence of 0V patterns (19±4 vs. 33±3%) and a higher 2UV (38±5 vs. 22±2%) in sham-operated rats that received DOXI. In rats with MI, DOXI symbolic indices were found to be similar. Our findings strongly suggest that 4-weeks of treatment with DOXI lead to a change in sympathovagal balance to the parasympathetic side. Curiously this effect was seen only in sham-operated but not in infarcted rats. Funding Sources: Fundação de Amparo à Pesquisa do Estados de São Paulo - FAPESP, 2020/06043-7. Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq, Process 306994/2021-6. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Objetivo: Identificar nas principais bases de dados os entraves evidenciados e os facilitadores do processo de liderança pelo enfermeiro na Estratégia Saúde da Família. Métodos: Revisão integrativa da literatura realizada através dos descritores “Enfermagem”, “Liderança” e “Estratégia Saúde da Família” nas Base de dados da LILACS, MEDLINE, BDENF e SciELO. Resultados: A liderança pelo enfermeiro emergiu em todos os artigos selecionados, elucidando a relevância desse profissional como responsável por orientar e direcionar processos de trabalho. A comunicação, as relações interpessoais, a sobrecarga de trabalho, a autonomia e a educação permanente foram considerados elementos chave para o exercício da liderança, sendo identificados ora como facilitadores ora como entraves. Considerações finais: Os achados do estudo sinalizam a necessidade de novas pesquisas de base qualitativa na perspectiva de compreender, não só como a liderança do enfermeiro na Estratégia de Saúde da Família tem se conformado, mas, se os entraves e facilitadores encontrados na literatura persistem na atualidade.
This work aimed to perform a virtual screening using a covalent docking and MM-PBSA protocol in an FDA-approved drugs library dataset to search for new compounds useful against this cruzain. Initially, 1615 FDAapproved compounds were visually inspected for the presence of chemical groups reactive against cruzain reactive cysteine (Cys 25 ), followed by the choice of the most suitable 3D structure for the virtual protocols. Thus, 241 compounds were selected and the covalent docking assays and the drugs with a fit score covalent greater than 100, were selected to the MM-PBSA calculations. Finally, the drugs neratinib, sacubitril, alprostadil, trandolapril, and florbetapir showed a covalent fit score between 102. 14 and 116.59;811 Kcal/mol calculated by MM-PBSA; and interactions with the key residues of the cruzain (Cys 25 , His 159 , Gly 23 , and Gly 65 ), showing best values than other cruzain inhibitors experimentally assayed. Our findings suggest that these drugs may be possible cruzain inhibitors, and biological assays should be performed to confirm their potential.
Recent studies on systemic lupus erythematosus (SLE) have reported more favorable outcomes thanks to better knowledge of the disease, more expert management of it, and rational use of treatments.
In this study we identified 301 SLE patients, seen between 1988 and 2019. Two hundred and twenty eight patients were treated in the public health system and 73 in private practice. In comparing both groups, we discovered that patients in the public health system were youn-ger at first consultation and at SLE onset and that the mean duration of their disease prior to first consultation was shorter in a statistically significant way. Also, they showed more frequence of leucopenia, Sm antibody, renal involvement and received I.V. corticosteroids.
Patients treated in the public system of health showed more accrual damage over the 10 first years of the disease than patients seen in the private system of health, but death in both groups was similar. Patients from both public and private groups were attended by medical specialist practices who made close follow-ups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.